CB 1 receptor inverse agonists

Details CB 1 receptor inverse agonists CB 1 receptor inverse agonists

2007-11-13

2007-11-13

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S423000, C548S335100, C548S537000

Reexamination Certificate

active

10743642

ABSTRACT:
The present invention relates to compounds of formula (I)wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

REFERENCES:
patent: 3940418 (1976-02-01), Hamilton
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 6613789 (2003-09-01), Khanna et al.
patent: 576357 (1993-12-01), None
patent: 656354 (1995-06-01), None
patent: 658546 (1995-06-01), None
patent: WO9602248 (1996-02-01), None
patent: WO9719063 (1997-05-01), None
patent: WO0015609 (2000-03-01), None
patent: WO0046209 (2000-08-01), None
patent: WO0132663 (2001-05-01), None
patent: WO0164632 (2001-09-01), None
patent: WO0164633 (2001-09-01), None
patent: WO0164634 (2001-09-01), None
patent: WO0170700 (2001-09-01), None
patent: WO0228346 (2002-04-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/027069 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 03/040107 (2003-05-01), None
Pacheco, M., et al., Aminoalkylindoles: Actions on Specific G-Protein-Linked Receptors, Journal of Pharmacology and Experimental Therapeutics, 1991, pp. 170-183, v. 257(1).
Casiano, F.M., et al., Putative Aminoalkylindoles (AAI) Antagonists, Problems of Drug Dependence 1990: Proceedings of the 52ndAnnual Scientific Meeting The Committeee on Problems of Drug Dependence, 1991, pp. 295-296, v. 105.
Hosohata, K., et al., AM630 is a Competitive Cannabinoid Receptor Antagonist in the Guinea Pig Brain, Life Sciences, 1997, pp. 115-118, v. 61(9).
Pertwee, R., et al., AM630, A Competitive Cannabinoid Receptor Antagonist, Life Sciences, 1995, pp. 1949-1955, v. 56(23/24).
Felder, C.C., et al., LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation, Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 291-297, v. 284(1).
Kanyonyo, M. et al., 3-Alkyl-(5,5'-Diphenyl) Imidazolidinediones As New Cannabinoid Ligands, Bioorganic & Medicinal Chemistry Letters, 1999, pp. 2233-2236, v. 9.
Ooms, F., et al., Exploration of the Pharmacophore of 3-Alkyl-5-Arylimidazolidinediones as New CB1Cannabinoid Receptor Ligands and Potential Antagonists: Synthesis, Lipophilicity, Affinity, and Molecular Modeling, J. Med. Chem., 2002, pp. 1748-1756, v. 45(9).

Affiliated with

Also associated with

Rating

CB 1 receptor inverse agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CB 1 receptor inverse agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CB 1 receptor inverse agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3812729